Thanks to the spillover effects of previous CIIE, GSK has introduced multiple innovative medical products, and accessibility is constantly accelerating. At this CIIE, its biopharmaceutical Benelux (Beliumab for Injection) has made another appearance. It is the only biopharmaceutical recommended by the Chinese guidelines, EULAR guidelines, and KDIGO guidelines, and has been approved by the China National Drug Administration for the treatment of systemic lupus erythematosus (SLE).
It is reported that lupus is a group of chronic autoimmune connective tissue diseases, with the most common being systemic lupus erythematosus. Thanks to the optimization of the national new drug review and approval policy, the introduction of relevant policies on medical insurance access, and the continuous spillover effect of the China International Import and Export Fair, the indications for adult and child systemic lupus erythematosus of Beiliteng have been successively included in the medical insurance catalog. At present, Beiliteng is actively promoting the medical insurance admission of adult lupus nephritis indications, hoping to benefit more patients.
Vice President and Head of GSK's China Specialty Medicine and Respiratory Business, Yu Jinyi, stated that the "Standardized Diagnosis and Treatment Project for Systemic Lupus Erythematosus" jointly initiated by GSK, the National Clinical Research Center for Skin and Immune Diseases, and the China Medical and Health Development Fund is continuously advancing.